Allakos Inc reports results for the quarter ended in December - Earnings Summary
Allakos Inc expected to post a loss of $1.31 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Advance Auto Parts, Airbnb, Marriott
U.S. RESEARCH ROUNDUP-Blackstone Secured Lending Fund, Extreme Networks, Silverbox Engaged Merger
U.S. STOCKS ON THE MOVE-Nikola, SciPlay, Crocs, 22nd Century Group
U.S. STOCKS ON THE MOVE-Tesla, InnovAge, Nikola, FedEx
U.S. STOCKS ON THE MOVE-Crocs, Kaixin, Ortho Clinical, JD.com
U.S. STOCKS ON THE MOVE-Travel and cruise stocks, Allakos, Tesla
Allakos eyes recovery, retailers flock to drugmaker
Diagnostics, Williams-Sonoma, Cytokinetics
U.S. STOCKS ON THE MOVE-Vaccine makers, SeaChange, Voya Financial, BiondVax
U.S. STOCKS ON THE MOVE-Reliance Global, Allakos, Acasti Pharma, CalAmp Corp
Allakos crashes after mixed data from lead drug trial
NASDAQ RESUMED AT 07:10 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
Brief: Allakos Says Topline Phase 3 Data From The Enigma 2 Study And Phase 2/3 Data From The Kryptos Study In Patients With Eosinophilic Gastrointestinal Diseases
NASDAQ TRADE HALT HALT NEWS DISSEMINATION AT 07:21 PM
Brief: Allakos Announces Expansion Of Lirentelimab Development Into Atopic Dermatitis, Chronic Spontaneous Urticaria And Asthma
Allakos Inc reports results for the quarter ended in September - Earnings Summary